Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2013 1
2014 1
2015 1
2016 3
2017 5
2018 4
2019 5
2020 3
2021 2
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F, Petrella M, Berno T, Binotto G, Bonetto G, Branca A, Carraro M, Cavaretta CA, Cellini A, D'Amore F, Forlani L, Gianesello I, Gurrieri C, Imbergamo S, Lessi F, Maroccia A, Mazzetto F, Pavan L, Pezone S, Piazza F, Pravato S, Ruocco V, Scapinello G, Vianello F, Zambello R, Zatta I, Zoletto S, Padoan A, Trentin L, Visentin A. Angotzi F, et al. Among authors: imbergamo s. Front Oncol. 2023 Jun 22;13:1212752. doi: 10.3389/fonc.2023.1212752. eCollection 2023. Front Oncol. 2023. PMID: 37427126 Free PMC article.
Current and future management of Ph/BCR-ABL positive ALL.
Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin AM, Vespignani M, Bassan R. Maino E, et al. Among authors: imbergamo s. Expert Rev Anticancer Ther. 2014 Jun;14(6):723-40. doi: 10.1586/14737140.2014.895669. Epub 2014 Mar 10. Expert Rev Anticancer Ther. 2014. PMID: 24611626 Review.
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A, Frezzato F, Severin F, Imbergamo S, Pravato S, Romano Gargarella L, Manni S, Pizzo S, Ruggieri E, Facco M, Brunati AM, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: imbergamo s. Onco Targets Ther. 2020 Sep 29;13:9679-9688. doi: 10.2147/OTT.S268899. eCollection 2020. Onco Targets Ther. 2020. PMID: 33061448 Free PMC article. Review.
Multifocal recurrent neuralgic amyotrophy in an immunocompromised patient.
Briani C, Salvalaggio A, Anglani M, Imbergamo S, Pravato S, Marasca M, Cacciavillani M, Gasparotti R. Briani C, et al. Among authors: imbergamo s. J Neurol. 2024 Mar;271(3):1080-1083. doi: 10.1007/s00415-023-12157-4. Epub 2024 Jan 7. J Neurol. 2024. PMID: 38184820 No abstract available.
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
Voso MT, Pandzic T, Falconi G, Denčić-Fekete M, De Bellis E, Scarfo L, Ljungström V, Iskas M, Del Poeta G, Ranghetti P, Laidou S, Cristiano A, Plevova K, Imbergamo S, Engvall M, Zucchetto A, Salvetti C, Mauro FR, Stavroyianni N, Cavelier L, Ghia P, Stamatopoulos K, Fabiani E, Baliakas P. Voso MT, et al. Among authors: imbergamo s. Br J Haematol. 2022 Jul;198(1):103-113. doi: 10.1111/bjh.18129. Epub 2022 Mar 11. Br J Haematol. 2022. PMID: 35277855
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, Ruocco V, Imbergamo S, Piazza F, Proietti G, Mauro FR, Trentin L. Visentin A, et al. Among authors: imbergamo s. Curr Oncol. 2022 Dec 25;30(1):274-283. doi: 10.3390/curroncol30010022. Curr Oncol. 2022. PMID: 36661671 Free PMC article.
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia.
Frezzato F, Visentin A, Severin F, Pizzo S, Ruggeri E, Mouawad N, Martinello L, Pagnin E, Trimarco V, Tonini A, Carraro S, Pravato S, Imbergamo S, Manni S, Piazza F, Brunati AM, Facco M, Trentin L. Frezzato F, et al. Among authors: imbergamo s. Cancers (Basel). 2021 Oct 29;13(21):5453. doi: 10.3390/cancers13215453. Cancers (Basel). 2021. PMID: 34771616 Free PMC article.
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: imbergamo s. Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5. Br J Haematol. 2019. PMID: 29974955 Free article. No abstract available.
28 results